Deutetrabenazine Composition With Controlled Impurity Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for high-quality pharmaceutical compositions of deutetrabenazine that maintain stability over time, particularly in the presence of specific impurities such as Compound 1 and Compound 2, to ensure safety and efficacy in treating hyperkinetic movement disorders.
Innovation Solution
The compositions comprise deutetrabenazine with controlled levels of Compound 1 (0.5 area-% or less) and Compound 2 (0.15 area-% or less), ensuring stability when stored at room temperature for up to 24 months, along with processes for isolating and testing these impurities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If deutetrabenazine is stored at room temperature over time, then the drug remains accessible and easy to use, but impurity levels increase and stability decreases
Solution Approach 1:
The patent performs stability-testing in advance to establish impurity thresholds before commercial distribution. By determining the impurity profiles of Compound 1 and Compound 2 through preliminary stability studies at room temperature, the patent sets acceptance criteria (0.5 area-% for Compound 1 and 0.15 area-% for Compound 2) that ensure drug stability is maintained throughout the shelf life, resolving the contradiction between storage convenience and stability.
2Reliability
If impurity levels are strictly controlled, then drug safety and quality are improved, but manufacturing complexity and cost increase
Solution Approach 1:
The patent establishes specific quantitative parameter thresholds for impurity levels (0.5 area-% for Compound 1 and 0.15 area-% for Compound 2) based on stability study data. By converting the qualitative requirement of 'drug safety' into quantitative impurity thresholds, the patent simplifies manufacturing control while ensuring reliability, as manufacturers can directly monitor and control these specific parameters without needing complex additional processes.
3Measurement precision
If comprehensive impurity testing is performed, then impurity detection accuracy is improved, but testing time and resource requirements increase
Solution Approach 1:
The patent extracts and focuses testing efforts on only the two most significant impurities (Compound 1 and Compound 2) that were identified through preliminary stability studies. By isolating these specific impurities as the primary testing targets rather than performing comprehensive testing on all possible impurities, the patent achieves high measurement precision for the critical impurities while significantly reducing testing time and resource requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions provide stable deutetrabenazine formulations that maintain impurity levels within safe limits, ensuring effective treatment of hyperkinetic movement disorders like Huntington's disease and other conditions.
Implementation Method 1
based on a determination by an HPLC method
Data Source
AI summary
The disclosure is directed to deutetrabenazine analogs, compositions comprising same and methods of detecting same in compositions comprising deutetrabenazine.